BMTCN Study
Myeloid - Answer -erythrocyte, platelets, neutrophil, basophil, eosinophil, monoblast, macrophage,
monocyte
lymphoid - Answer -pre- B cell, pre-t cell, plasma cell, natural killer cell, t lymphocyte
innate immunity - Answer -occurs naturally- phagocytes release inflammatory mediators
acquired immunity - Answer -response of either b or t cells to antigens
senescence - Answer -loss of cells power to divide and grow
immunosenescence - Answer -reduction in size of thymus and function of immune cells
first responders - Answer -myeloid
second responders - Answer -lymphoid- pathogen specific
syngeneic - Answer -identical twin, don't need immunosuppression, con- no graft vs tumor effect
, graft vs. tumor effect - Answer --promoted by withdrawal of immunosuppressant therapy
-promoted by DLIs
-dec. in absence of acute gvhd
-higher rate of relapse
DLI - Answer -infusion of lymphocytes from donor given when there is relapsed disease. Attempt to
create GVT effect
PBSCT - Answer -- 70 %, - faster engraftment, no anesthesia risks, dec. likelihood of contamination by
tumor, -higher risk of gvhd, - but better gvt effect- so dosent make sense for SCD
G-CSF - Answer -filgrastim. a glycoprotein stimulates the production of stem cells by binding to certain
cell surface areas
GM-CSF - Answer -sargramostim. lower stem cell yields. and inc adverse events. similar mechanism of
action
chemo induced mobilization - Answer -chemo causes reduction in production of blood cells thus
stimulating hematapoetic recovery.
-cyclophosphamide
-paclitaxel
-etoposide
-cytarabine
-improved mobilization
-more rapid engraftment
-reduced risk of tumor cell contamination
chemokine antagonist mobilization - Answer -directly induce mobilization by working as antagonist
between the chemokine stromal-derived-factor- 1 and receptor CXCR4.
-Plerixafor
Myeloid - Answer -erythrocyte, platelets, neutrophil, basophil, eosinophil, monoblast, macrophage,
monocyte
lymphoid - Answer -pre- B cell, pre-t cell, plasma cell, natural killer cell, t lymphocyte
innate immunity - Answer -occurs naturally- phagocytes release inflammatory mediators
acquired immunity - Answer -response of either b or t cells to antigens
senescence - Answer -loss of cells power to divide and grow
immunosenescence - Answer -reduction in size of thymus and function of immune cells
first responders - Answer -myeloid
second responders - Answer -lymphoid- pathogen specific
syngeneic - Answer -identical twin, don't need immunosuppression, con- no graft vs tumor effect
, graft vs. tumor effect - Answer --promoted by withdrawal of immunosuppressant therapy
-promoted by DLIs
-dec. in absence of acute gvhd
-higher rate of relapse
DLI - Answer -infusion of lymphocytes from donor given when there is relapsed disease. Attempt to
create GVT effect
PBSCT - Answer -- 70 %, - faster engraftment, no anesthesia risks, dec. likelihood of contamination by
tumor, -higher risk of gvhd, - but better gvt effect- so dosent make sense for SCD
G-CSF - Answer -filgrastim. a glycoprotein stimulates the production of stem cells by binding to certain
cell surface areas
GM-CSF - Answer -sargramostim. lower stem cell yields. and inc adverse events. similar mechanism of
action
chemo induced mobilization - Answer -chemo causes reduction in production of blood cells thus
stimulating hematapoetic recovery.
-cyclophosphamide
-paclitaxel
-etoposide
-cytarabine
-improved mobilization
-more rapid engraftment
-reduced risk of tumor cell contamination
chemokine antagonist mobilization - Answer -directly induce mobilization by working as antagonist
between the chemokine stromal-derived-factor- 1 and receptor CXCR4.
-Plerixafor
